Beijing South Region Oncology Hospital

CancerFax acts as your single coordinator for the entire BSROH journey. You begin by sharing your medical records, including pathology reports, recent imaging, prior treatment summaries and any molecular or biomarker testing through our secure intake. Our clinical team reviews your case and identifies whether BSROH is genuinely the right hospital for your specific diagnosis, and equally importantly, whether a larger Chinese academic cancer hospital (such as Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing Cancer Hospital directly, Lu Daopei Hospital for haematology, or Sun Yat-sen University Cancer Center) would serve you better. We submit your records to BSROH's International Department and confirm in advance which visiting consultant from Beijing Cancer Hospital or other Grade A tertiary hospitals will be assigned to your case.

Once a clinical plan is confirmed, CancerFax prepares your full pre-travel pack: BSROH's official cost estimate (shared with you without any CancerFax mark-up), Chinese visa documentation, accredited translation of your home-country reports, accommodation guidance in Daxing District, and where useful a comparison against treatment plans and costs at other Chinese cancer hospitals. We remain your single point of contact through admission, treatment and follow-up. There is no fee to the patient for any of this coordination, and we will tell you openly if BSROH is not the right hospital for your case rather than recommending it by default.

No. This distinction is important and CancerFax wants to be very clear about it. Beijing Cancer Hospital is Peking University Cancer Hospital (Peking University School of Oncology), a major Grade III Class A public academic cancer hospital affiliated with Peking University. Beijing South Region Oncology Hospital (BSROH) is a separate private oncology hospital founded in 2012, located in Daxing District in southern Beijing, and operated as a member of Asia-Pacific Medical Group. BSROH publicly positions itself as a cooperative medical institution of Beijing Cancer Hospital, meaning that senior consultant oncologists from Beijing Cancer Hospital (and other Grade A tertiary hospitals) serve as visiting consultants at BSROH. This is a clinical cooperation, not an institutional ownership or branch relationship. Patients should not assume that treatment at BSROH is the same as treatment at Beijing Cancer Hospital, and CancerFax will help you understand the practical differences for your specific case before any travel.

BSROH actively markets several advanced therapies through its Treatment Center: HIFU (high-intensity focused ultrasound) ablation, microwave ablation, hyperthermia, the AI Epic Co-Ablation System and a CAR-T cell therapy programme. The evidence base for each of these varies meaningfully by cancer type and clinical context. Microwave ablation is well established for selected small liver tumours and is recommended in international guidelines for specific indications. HIFU has stronger evidence in some indications (such as prostate and uterine fibroid treatment) than in others (such as late-stage pancreatic cancer, where it is typically used as a palliative adjunct rather than a curative therapy). Hyperthermia is generally used as an adjunct to chemotherapy or radiotherapy, with variable evidence by cancer type. CAR T-cell therapy in China is well established for selected hematologic malignancies, but the specific CAR-T products, target antigens and indications offered at BSROH should be confirmed directly with the International Department. CancerFax will give you an honest, evidence-based view of which of these modalities is appropriate for your specific diagnosis rather than relying on marketing claims.

Yes. BSROH's International Department accepts foreign-language medical records and can provide a preliminary written opinion based on your submission. CancerFax facilitates this submission, coordinates accredited translation of your reports into Chinese, follows up on your behalf and helps you understand the resulting opinion, including how it compares with treatment plans from other top cancer centres in China and internationally. A remote opinion is particularly useful here because, given the cooperative consultant model at BSROH, CancerFax can confirm in advance which visiting consultant from Beijing Cancer Hospital or other Grade A hospitals will be involved in your in-person care if you do travel, and what specifically they will and will not be able to offer at BSROH versus at their primary public hospital.

As a private oncology hospital, BSROH's pricing is typically higher than the equivalent treatment cost at China's national public cancer hospitals (such as Cancer Hospital of the Chinese Academy of Medical Sciences or Beijing Cancer Hospital directly), where the same visiting consultants also practise. Patients are paying a meaningful premium for the smaller-volume private hospital environment, the multilingual International Department and the integrative treatment options, rather than for fundamentally different clinical capability. At the same time, BSROH's pricing is typically lower than equivalent care at high-end private international hospitals in China (such as Shanghai Jiahui International Hospital), and substantially lower than care in the United States, Western Europe or Singapore. CancerFax shares BSROH's official cost estimates with you at no extra charge and without any CancerFax mark-up, and we are happy to compare them openly with both the public Chinese cancer hospital alternatives and the private international cancer hospital alternatives before any decision is made.